

**cPLA2-ε Polyclonal Antibody**


<b>Catalog No :</b>	YT1087
<b>Reactivity :</b>	Human;Mouse
<b>Applications :</b>	IHC;IF;ELISA
<b>Target :</b>	cPLA2-ε
<b>Fields :</b>	>>Glycerophospholipid metabolism;>>Ether lipid metabolism;>>Arachidonic acid metabolism;>>Linoleic acid metabolism;>>alpha-Linolenic acid metabolism;>>Metabolic pathways;>>MAPK signaling pathway;>>Ras signaling pathway;>>Phospholipase D signaling pathway;>>Necroptosis;>>Vascular smooth muscle contraction;>>VEGF signaling pathway;>>Platelet activation;>>Fc epsilon RI signaling pathway;>>Fc gamma R-mediated phagocytosis;>>Glutamatergic synapse;>>Serotonergic synapse;>>Long-term depression;>>Inflammatory mediator regulation of TRP channels;>>GnRH signaling pathway;>>Ovarian steroidogenesis;>>Oxytocin signaling pathway;>>Choline metabolism in cancer
<b>Gene Name :</b>	PLA2G4E
<b>Protein Name :</b>	Cytosolic phospholipase A2 epsilon
<b>Human Gene Id :</b>	123745
<b>Human Swiss Prot No :</b>	Q3MJ16
<b>Mouse Swiss Prot No :</b>	Q50L42
<b>Immunogen :</b>	The antiserum was produced against synthesized peptide derived from human PLA2G4E. AA range:401-450
<b>Specificity :</b>	cPLA2-ε Polyclonal Antibody detects endogenous levels of cPLA2-ε protein.
<b>Formulation :</b>	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
<b>Source :</b>	Polyclonal, Rabbit,IgG
<b>Dilution :</b>	IHC 1:100 - 1:300. ELISA: 1:40000.. IF 1:50-200

---

<b>Purification :</b>	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
<b>Concentration :</b>	1 mg/ml
<b>Storage Stability :</b>	-15°C to -25°C/1 year(Do not lower than -25°C)
<b>Molecularweight :</b>	96kD
<b>Cell Pathway :</b>	Glycerophospholipid metabolism;Ether lipid metabolism;Arachidonic acid metabolism;Linoleic acid metabolism;alpha-Linolenic acid metabolism;MAPK_ERK_Growth;MAPK_G_Protein;Vascular smooth muscle contrac
<b>Background :</b>	catalytic activity:Phosphatidylcholine + H(2)O = 1-acylglycerophosphocholine + a carboxylate.,domain:The N-terminal C2 domain associates with lipid membranes and mediates its regulation by presenting the active site to its substrate in response to elevations of cytosolic Ca(2+).,enzyme regulation:Stimulated by cytosolic Ca(2+).,function:Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position.,similarity:Contains 1 C2 domain.,similarity:Contains 1 PLA2c domain.,subcellular location:Translocates to lysosomal membranes in a calcium-dependent fashion.,
<b>Function :</b>	catalytic activity:Phosphatidylcholine + H(2)O = 1-acylglycerophosphocholine + a carboxylate.,domain:The N-terminal C2 domain associates with lipid membranes and mediates its regulation by presenting the active site to its substrate in response to elevations of cytosolic Ca(2+).,enzyme regulation:Stimulated by cytosolic Ca(2+).,function:Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position.,similarity:Contains 1 C2 domain.,similarity:Contains 1 PLA2c domain.,subcellular location:Translocates to lysosomal membranes in a calcium-dependent fashion.,
<b>Subcellular Location :</b>	Cytoplasm, cytosol . Early endosome membrane ; Peripheral membrane protein ; Cytoplasmic side . Lysosome membrane ; Peripheral membrane protein ; Cytoplasmic side . Cell membrane ; Peripheral membrane protein; Cytoplasmic side . Targeted to clathrin-independent endocytotic vesicles through binding to phosphoinositides, especially phosphatidylinositol 4,5-bisphosphates. .
<b>Expression :</b>	Heart,Lung,Tongue,

---

## Products Images



Immunohistochemistry analysis of paraffin-embedded human lung carcinoma, using PLA2G4E Antibody. The picture on the right is blocked with the synthesized peptide.